In GETUG AFU 18, did dose escalated prostate radiation improve clinical progression free survival compared with lower dose RT in the setting of long term ADT for high risk prostate cancer?
In the SHARE trial, was there a higher rate of late grade 2+ effects with moderately hypofractionated prostate fossa radiation?
What TNT trial recently reported improved survival for locally advanced rectal cancer?
For lower risk rectal cancer, did short course RT or long course chemoRT have better chances of organ preservation in the STAR-TREC trial?
Answers
Yes, 84% v 72% at 10 years. There was also better prostate cancer specific survival and even overall survival with dose escalation.
Yes, 8% v <1%, with 65 Gy in 26 fractions versus 66 Gy in 33 fractions. However, the authors noted these events resolved in further follow up. The trial showed no improvement in biochemical control.
STELLAR, where short course RT, 4 cycles of capeox, surgery, and 2 more cycles of capeox improved OS at 5 years (78% v 70%).
Long course CRT. Among those who elected the organ preservation approach, TME free survival was higher with LCCRT than SCRT (79% v 61%) driven by a higher clinical complete response rate (64% v 36%). | QuadShot News
In the SHARE trial, was there a higher rate of late grade 2+ effects with moderately hypofractionated prostate fossa radiation?
What TNT trial recently reported improved survival for locally advanced rectal cancer?
For lower risk rectal cancer, did short course RT or long course chemoRT have better chances of organ preservation in the STAR-TREC trial?
Answers
Yes, 84% v 72% at 10 years. There was also better prostate cancer specific survival and even overall survival with dose escalation.
Yes, 8% v <1%, with 65 Gy in 26 fractions versus 66 Gy in 33 fractions. However, the authors noted these events resolved in further follow up. The trial showed no improvement in biochemical control.
STELLAR, where short course RT, 4 cycles of capeox, surgery, and 2 more cycles of capeox improved OS at 5 years (78% v 70%).
Long course CRT. Among those who elected the organ preservation approach, TME free survival was higher with LCCRT than SCRT (79% v 61%) driven by a higher clinical complete response rate (64% v 36%). | QuadShot News